Intelligence and Neurodevelopmental Disorders After Prenatal Exposure to General Anaesthesia
Launched by UNIVERSITAIRE ZIEKENHUIZEN KU LEUVEN · Oct 7, 2024
Trial Information
Current as of July 22, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Prenatal anaesthesia exposure:
- Inclusion Criteria:
- • Prenatal anaesthesia exposure: Children exposed in utero to maternal general anaesthesia to allow laparoscopy or laparotomy for appendicectomy, adnexal pathology, cholecystectomy or for diagnostic procedures to rule out intra-abdominal pathology
- • No prenatal anaesthesia exposure: Children not exposed to general anaesthesia for non-obstetric or obstetric (e.g. cesarean section) surgery in utero
- • Children born in 2000-2023
- • (Parental) informed consent
- Exclusion Criteria:
- • Children whose mothers underwent obstetric surgery or foetal surgery/interventions during the same pregnancy.
- • No Dutch-speaking children
- • Diagnosis of severe disability of genetic origin (e.g., Fragil X, Down syndrome,...), history of head trauma, major congenital birth defects
About Universitaire Ziekenhuizen Ku Leuven
Universitaire Ziekenhuizen KU Leuven is a leading academic medical center in Belgium, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. Affiliated with KU Leuven, one of Europe’s premier universities, the institution integrates cutting-edge scientific inquiry with high-quality patient care. It plays a pivotal role in the development and implementation of clinical trials, fostering collaboration between researchers, healthcare professionals, and industry partners to translate scientific discoveries into effective treatments. The hospital's multidisciplinary approach ensures comprehensive patient safety and ethical standards, positioning it as a trusted sponsor in the realm of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Leuven, Vlaams Brabant, Belgium
Bonheiden, Antwerpen, Belgium
Roeselare, West Flanders, Belgium
Patients applied
Trial Officials
Sarah Devroe, MD, Phd
Principal Investigator
UZ Leuven
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported